Literature DB >> 24763914

Prognostic value of clinical and pathologic T stages defined by the American Joint Committee on Cancer for eyelid sebaceous carcinoma in Korea.

Youn Joo Choi1, Hyun Chul Jin, Min Joung Lee, Namju Kim, Ho-Kyung Choung, Sang In Khwarg.   

Abstract

PURPOSE: To investigate whether the clinical and pathologic T category classification, as defined by the American Joint Committee on Cancer (AJCC), is associated with lymph nodes (LN) or distant metastasis in patients with eyelid sebaceous carcinoma.
METHODS: Forty patients treated for eyelid sebaceous carcinoma at Seoul National University Hospital between March 1999 and December 2011 were retrospectively staged according to the AJCC 7th edition criteria. Three different primary tumor classifications-(1) clinical tumor size at presentation; (2) clinical AJCC T stage (cT) at presentation based not only on size, but also on the extent of involvement and (3) pathologic AJCC T stage (pT) based on histopathological examination-were compared and evaluated with regard to their association with LN or distant metastasis.
RESULTS: In univariate analysis, the AJCC cT (p = 0.005) and pT (p = 0.029) categories were significantly associated with metastasis, but clinical tumor size alone did not correlate with metastasis (p = 0.093). Clinical and pathologic AJCC stage T2b or higher tumors were significantly associated with metastasis compared to stage T1 or T2a tumors [odds ratio cT, 8.00 (p = 0.025); pT, 6.91 (p = 0.028)].
CONCLUSIONS: The clinical and pathologic AJCC T category has predictive value for LN or distant metastasis in eyelid sebaceous carcinoma. However, the clinically assessed largest tumor dimension alone is not an effective predictive factor. Clinicians should be aware of the increased risk of metastasis in patients with tumors of stage T2b or higher at initial presentation.

Entities:  

Mesh:

Year:  2014        PMID: 24763914     DOI: 10.1007/s10384-014-0321-9

Source DB:  PubMed          Journal:  Jpn J Ophthalmol        ISSN: 0021-5155            Impact factor:   2.447


  16 in total

Review 1.  Sebaceous and meibomian carcinomas of the eyelid. Recognition, diagnosis, and management.

Authors:  J A Khan; J F Doane; A S Grove
Journal:  Ophthalmic Plast Reconstr Surg       Date:  1991       Impact factor: 1.746

Review 2.  Sebaceous carcinoma of the ocular region: a review.

Authors:  Jerry A Shields; Hakan Demirci; Brian P Marr; Ralph C Eagle; Carol L Shields
Journal:  Surv Ophthalmol       Date:  2005 Mar-Apr       Impact factor: 6.048

3.  Sentinel lymph node biopsy in patients with conjunctival and eyelid cancers: experience in 17 patients.

Authors:  Toufic J Maalouf; Gilles Dolivet; Karine S Angioi; Agnes Leroux; Pascal Genin; Jean-Luc George
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2012 Jan-Feb       Impact factor: 1.746

4.  Epidemiology of sebaceous carcinoma of the head and neck: implications for lymph node management.

Authors:  Geir Tryggvason; Rodrigo Bayon; Nitin A Pagedar
Journal:  Head Neck       Date:  2012-01-20       Impact factor: 3.147

Review 5.  Sentinel lymph node biopsy for eyelid and conjunctival tumors: what have we learned in the past decade?

Authors:  Margaret L Pfeiffer; Aaron Savar; Bita Esmaeli
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2013 Jan-Feb       Impact factor: 1.746

6.  Outcome of patients with periocular sebaceous gland carcinoma with and without conjunctival intraepithelial invasion.

Authors:  A N Chao; C L Shields; H Krema; J A Shields
Journal:  Ophthalmology       Date:  2001-10       Impact factor: 12.079

7.  Positive sentinel node in sebaceous carcinoma of the eyelid.

Authors:  Aaron Savar; Patrick Oellers; Jeffrey Myers; Victor G Prieto; Carlos Torres-Cabala; Steven J Frank; Doina Ivan; Bita Esmaeli
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2011 Jan-Feb       Impact factor: 1.746

8.  Sentinel lymph node biopsy for sebaceous cell carcinoma and melanoma of the ocular adnexa.

Authors:  Viet H Ho; Merrick I Ross; Victor G Prieto; Aisha Khaleeq; Stella Kim; Bita Esmaeli
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2007-08

9.  Introduction of the 7th edition eyelid carcinoma classification system from the American Joint Committee on Cancer-International Union Against Cancer staging manual.

Authors:  Darryl J Ainbinder; Bita Esmaeli; Stephen C Groo; Paul T Finger; Joseph P Brooks
Journal:  Arch Pathol Lab Med       Date:  2009-08       Impact factor: 5.534

10.  Application of the AJCC 7th edition carcinoma of the eyelid staging system: a medical center pathology based, 15-year review.

Authors:  Courtney Crawford; Colby Fernelius; Paula Young; Stephen Groo; Darryl Ainbinder
Journal:  Clin Ophthalmol       Date:  2011-11-18
View more
  5 in total

Review 1.  Surgical Management of Periocular Cancers: High- and Low-Risk Features Drive Treatment.

Authors:  Richard C Allen
Journal:  Curr Oncol Rep       Date:  2017-09       Impact factor: 5.075

2.  CDKN2A, CDK1, and CCNE1 overexpression in sebaceous gland carcinoma of eyelid.

Authors:  Tatsuya Yunoki; Tetsushi Hirano; Yoshiaki Tabuchi; Yukihiro Furusawa; Misako Torigoe; Takahiko Nakajima; Johji Imura; Atsushi Hayashi
Journal:  Int Ophthalmol       Date:  2019-09-30       Impact factor: 2.031

Review 3.  Sebaceous Carcinoma: A Review of the Scientific Literature.

Authors:  Thomas Knackstedt; Faramarz H Samie
Journal:  Curr Treat Options Oncol       Date:  2017-08

4.  Postoperative interstitial brachytherapy in eyelid cancer: long term results and assessment of Cosmesis After Interstitial Brachytherapy scale.

Authors:  Sarbani Ghosh Laskar; Trinanjan Basu; Suresh Chaudhary; Devendra Chaukar; Mandar Nadkarni; Manjunatha Gn
Journal:  J Contemp Brachytherapy       Date:  2014-11-06

5.  Nordic treatment practices survey and consensus for treatment of eyelid sebaceous carcinoma.

Authors:  Tiina Leivo; Johanna Sarmela; Maria Enckell-Aaltonen; Eva Dafgård Kopp; Caroline Schmitt; Peter B Toft; Haraldur Sigurdsson; Marita Uusitalo
Journal:  BMC Ophthalmol       Date:  2020-03-16       Impact factor: 2.209

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.